Novo Nordisk is working on a new obesity drug that could help ... Semaglutide, the GLP-1 drug that Novo sells under the brand ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

the chief executive of Ozempic maker Novo Nordisk warned Wednesday. “Honestly, I’m quite alarmed by what we see in the US now ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

Novo Nordisk said on Wednesday it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...